Exicure Current Ratio 2017-2021 | XCUR

Exicure current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Exicure Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.06B $0.01B 4.76
2021-03-31 $0.07B $0.01B 5.80
2020-12-31 $0.09B $0.01B 6.29
2020-09-30 $0.10B $0.01B 7.68
2020-06-30 $0.09B $0.01B 6.22
2020-03-31 $0.10B $0.02B 4.99
2019-12-31 $0.11B $0.03B 3.63
2019-09-30 $0.07B $0.01B 8.67
2019-06-30 $0.02B $0.01B 2.32
2019-03-31 $0.02B $0.01B 2.87
2018-12-31 $0.03B $0.00B 13.54
2018-09-30 $0.03B $0.01B 3.69
2018-06-30 $0.02B $0.00B 4.24
2018-03-31 $0.02B $0.00B 7.64
2017-12-31 $0.03B $0.00B 8.24
2017-09-30 $0.02B $0.01B 2.31
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.113B $0.017B
Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71